TRDA — ENTRADA THERAPEUTICS INC

Ownership history in ROYCE & ASSOCIATES LP  ·  3 quarters on record

This page tracks every 13F SEC filing in which ROYCE & ASSOCIATES LP reported a position in ENTRADA THERAPEUTICS INC (TRDA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.03% (2025 Q4)
Avg. % of fund
0.02%
First filed
2025 Q2
Last filed
2025 Q4
Quarters held
3
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 247,147 -98,360 -28.5% 0.03% $2.5M $10.28
2025 Q3 ADDED 345,507 +122,256 +54.8% 0.02% $2.0M $5.80
2025 Q2 INITIATED 223,251 — — 0.02% $1.5M $6.72
% of Fund (quarterly)    TRDA price (monthly, adj. close)

Other funds also holding TRDA

As of 2025 Q4 — sorted by position size

5AM Venture Management, LLC 3Y 13.11% StepStone Group LP 3Y 7Y 4.19% TCG Crossover Management, LLC 3Y 0.71% Nan Fung Group Holdings Ltd 3Y 0.45% BAKER BROS. ADVISORS LP 3Y 7Y 0.31% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 0.22% Lynx1 Capital Management LP 3Y 0.11% Dynamic Technology Lab Private Ltd 3Y 7Y 0.06% XTX Topco Ltd 3Y 0.03% AXQ CAPITAL, LP 3Y 0.02%
← Back to ROYCE & ASSOCIATES LP Holdings